Search results for " Immunologic"

showing 10 items of 538 documents

Partial and Ineffective Activation of Vγ9Vδ2 T Cells by Mycobacterium tuberculosis-Infected Dendritic Cells

2010

Abstract γδ T cells and dendritic cells (DCs) participate in early phases of immune response against Mycobacterium tuberculosis. We investigated whether a close functional relationship exists between these two cell populations using an in vitro coculture in a human system. Vγ9Vδ2 T cells induce full maturation of M. tuberculosis-infected immature DCs, as demonstrated by upregulation of the costimulatory CD80, CD86, CD40, and HLA-DR molecules on infected DCs after 24 h of coculture. Reciprocally, infected DCs induced substantial activation of Vγ9Vδ2 T cells upon coculture, which was cell-to-cell contact and TCR dependent, as demonstrated in transwell experiments. However, infected DCs select…

AdultMaleImmunologyAntigen presentationchemical and pharmacologic phenomenaBiologyLymphocyte ActivationImmunophenotypingInterleukin 21T-Lymphocyte SubsetsCell Line TumorHumansImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellgamma delta T cells Mycobacterium tuberculosis dendritic cellsCells CulturedCD86Cell DifferentiationReceptors Antigen T-Cell gamma-deltaDendritic CellsMycobacterium tuberculosisMiddle AgedCytotoxicity Tests ImmunologicNatural killer T cellCoculture TechniquesCell biologyImmunologyFemaleImmunologic MemoryCD80T-Lymphocytes CytotoxicThe Journal of Immunology
researchProduct

Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.

1993

Abstract The haplotype HLA-B8,DR3 is over-represented in several autoimmune diseases, implying that genes predisposing people to these disorders are linked to this haplotype. In these diseases, various dysfunctions reflecting an impairment of the immune system have been found. Several reports indicate also that in HLA-B8,DR3-positive healthy subjects similar disorders may be demonstrated. In the present work, we have evaluated NK and LAK activity in these subjects. The study has been performed on monocyte-depleted peripheral blood MNCs by using the K-562 cell line as a target for NK activity and the HL-60 cell line for as a target LAK activity. LAK cells were obtained by incubating MNCs for…

AdultMaleImmunologyFluorescent Antibody TechniqueBiologyCD16Natural killer cellHLA-B8 AntigenImmune systemHLA-DR3 AntigenmedicineTumor Cells CulturedImmunology and AllergyHumansCytotoxicityKiller Cells Lymphokine-ActivatedLymphokine-activated killer cellHaplotypeReceptors IgGLymphokineGeneral MedicineCytotoxicity Tests ImmunologicKiller Cells Naturalmedicine.anatomical_structureHaplotypesCell cultureImmunologyInterleukin-2FemaleHuman immunology
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODI…

2021

Abstract Immune checkpoint inhibitors have failed in treating metastatic colorectal cancer (mCRC) patients except those with dMMR/MSI tumors. However, until very recently we had only non-comparative promising data in this population with anti-programmed cell death 1/ programmed cell death ligand 1 (PD1/PD-L1) antibodies alone or combined with anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies. This comparative phase II trial (NCT 03186326), conducted in more than 100 centers in France, will include dMMR/MSI mCRC patients with progression after a first-line treatment with chemotherapy ± targeted therapies, to evaluate efficacy and safety of the anti-PDL1 Avelumab versus a s…

AdultMaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationECOG Performance StatusAntibodies Monoclonal HumanizedAvelumab03 medical and health sciencesAntineoplastic Agents ImmunologicalClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopiceducationRandomized Controlled Trials as TopicChemotherapyeducation.field_of_studyHepatologybusiness.industryGastroenterologyMicrosatellite instabilityImmunotherapymedicine.diseaseProgression-Free SurvivalRegimen030220 oncology & carcinogenesisFemaleMicrosatellite Instability030211 gastroenterology & hepatologyFranceColorectal Neoplasmsbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma

2013

Objective: The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of immunotherapy contributes to asthma control. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered, before the pollen season, to 20 Parietaria-sensitive mild, untreated asthmatics (M/F: 12/8; age: 38 ± 14 years). After the screening visit (visit 1), asthma control was assessed by the Asthma Control Test (ACT) immediately before the fi…

AdultMalePulmonary and Respiratory MedicineBreath TestParietariamedicine.drug_classmedicine.medical_treatmentMonophosphoryl Lipid Aairway inflammationSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideAnti-inflammatoryAllergic symptomsmedicineHumansPharmacology (medical)LungAsthmaInflammationVaccinesbiologybusiness.industryAllergy vaccineImmunotherapyMiddle Agedmedicine.diseasebiology.organism_classificationAsthmaParietariaquality of lifeBreath TestsDesensitization ImmunologicImmunologyFemaleimmunotherapybusinessVaccineAdjuvantHumanTherapeutic Advances in Respiratory Disease
researchProduct

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008

Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition. Objective To examine the benefits and risks of long-term treatment with danazol. Methods Data were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected b…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbdominal painPediatricsImmunologyDose-Response Relationship ImmunologicRisk AssessmentSeverity of Illness IndexEcallantideSeverity of illnessmedicineHumansImmunology and AllergyAdverse effectDepression (differential diagnoses)Retrospective StudiesDanazolbusiness.industryDanazolAngioedemas HereditaryEstrogen AntagonistsMiddle Agedmedicine.diseaseSurgeryDiscontinuationHereditary angioedemaFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugAnnals of Allergy, Asthma & Immunology
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn diseas…

2000

The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1-5) can bind to cells lacking the IL-6 receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R) (trans signaling). Here, we have assessed the contribution of this system to the increased resistance of mucosal T cells against apoptosis in Crohn disease (CD), a chronic inflammatory disease of the gastrointestinal tract. A neutralizing antibody against IL-6R suppressed established experimental colitis in various animal models of CD mediated by type 1 T-helper cells, by inducing apoptosis of lamina propria T cells. Similarly, specific neutralization of sIL-6R in vivo by a newly designed gp130-Fc fusion protein caused suppr…

AdultMaleSTAT3 Transcription FactorT-Lymphocytesmedicine.medical_treatmentT cellbcl-X ProteinApoptosisGeneral Biochemistry Genetics and Molecular BiologyMiceCrohn DiseaseAntigenAntigens CDCytokine Receptor gp130medicineAnimalsHumansInterleukin 6Mice Inbred BALB CMembrane GlycoproteinsbiologyInterleukin-6Models ImmunologicalInterleukinGeneral MedicineMiddle AgedReceptors Interleukin-6DNA-Binding ProteinsCytokinemedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisImmunologyTrans-Activatorsbiology.proteinSTAT proteinCancer researchColitis UlcerativeFemaleSignal transductionProtein BindingSignal TransductionNature Medicine
researchProduct

Synovial fluid-derivedYersinia-reactive T cells responding to human 65-kDa heat-shock protein and heat-stressed antigen-presenting cells

1991

Humoral and cellular immune reactions to heat-shock proteins have been implicated in the pathogenesis of arthritis. Heat-shock proteins occur in bacteria as well as all eukaryotes and have been highly conserved during evolution. Cross-reactivity between bacterial and human heat-shock proteins induced at the site of inflammation may underlie the pathogenesis of some forms of arthritis. In order to test this hypothesis, we raised and cloned a Yersinia-specific T cell line from the synovial fluid lymphocytes of a patient with Yersinia-induced reactive arthritis. From this line we obtained a CD4+ T cell clone that proliferated in response to Yersinia antigens and both to the mycobacterial and t…

AdultMaleSalmonella typhimuriumHot TemperatureT-LymphocytesT cellImmunologyDose-Response Relationship ImmunologicAntigen-Presenting CellsArthritisCross ReactionsBiologyArthritis ReactiveImmune systemTetanus ToxinAntigenHeat shock proteinCandida albicansSynovial FluidEscherichia colimedicineHumansImmunology and AllergySynovial fluidAntigen-presenting cellHeat-Shock ProteinsT lymphocytebeta-Galactosidasemedicine.diseaseYersiniaCell biologymedicine.anatomical_structureImmunologyEuropean Journal of Immunology
researchProduct